| AMBRA1 levels predict resistance to MAPK inhibitors in melanoma L Di Leo, C Pagliuca, A Kishk, S Rizza, C Tsiavou, C Pecorari, C Dahl, ... Proceedings of the National Academy of Sciences 121 (25), e2400566121, 2024 | | 2024 |
| Suppressed basal mitophagy drives cellular aging phenotypes that can be reversed by a p62-targeting small molecule G Kelly, T Kataura, J Panek, G Ma, H Salmonowicz, A Davis, H Kendall, ... Dev Cell 59 (10.1016), 2024 | 1 | 2024 |
| The combined immunohistochemical expression of AMBRA1 and SQSTM1 identifies patients with poorly differentiated cutaneous squamous cell carcinoma at risk of metastasis: A proof … MH Alexander, WJ Cousins, T Ewen, AP South, P Lovat, N Stefanos Journal of Cutaneous Pathology 51 (6), 450-458, 2024 | | 2024 |
| Porcine‐derived collagen peptides promote re‐epithelialisation through activation of integrin signalling K Mistry, G Richardson, S Vleminckx, R Smith, E Gevaert, PE Lovat Wound Repair and Regeneration, 2024 | | 2024 |
| Método in vitro para determinar se um sujeito com melanoma tem um risco maior de desenvolver metástase M Labus, P Lovat, R Ellis | | 2024 |
| AMBRA1 is a predictive biomarker of melanoma response to targeted therapy L Di Leo, C Pagliuca, A Kishk, S Rizza, C Tsiavou, C Pecorari, C Dahl, ... EJC Skin Cancer 2, 2024 | | 2024 |
| Loss of AMBRA1 expression in the tumour endothelium as a potential biomarker to identify AJCC stage I/II melanomas at high risk of metastasis P Lovat, R Stout, K Best, P Sloan, J Armstrong EJC Skin Cancer 2, 2024 | | 2024 |
| Immunohistochemical analysis of AMBRA1 and loricrin expression reveals maintained expression in the epidermis overlying a range of benign melanocytic naevi but which may be … A Husain, P Lovat, G Richardson, T Ness, C Jones, C Graham, M Labus, ... EJC Skin Cancer 2, 2024 | | 2024 |
| Validation of Epidermal AMBRA1 and Loricrin (AMBLor) as a prognostic biomarker for non-ulcerated AJCC stage I/II cutaneous melanoma T Ewen, A Husain, N Stefanos, P Barrett, C Jones, T Ness, A Long, ... British Journal of Dermatology, 2023 | 3* | 2023 |
| Predictive accuracy of risk prediction models for recurrence, metastasis and survival for early-stage cutaneous melanoma: a systematic review TP Kunonga, RPW Kenny, M Astin, A Bryant, V Kontogiannis, D Coughlan, ... BMJ open 13 (9), e073306, 2023 | 2 | 2023 |
| O17 Endogenous double-stranded RNA (dsRNA) in melanoma: an attack from within S Sadeq, R Plummer, S Chitcharoen, P Lovat, G Nelson, A Werner British Journal of Dermatology 189 (1), e11-e12, 2023 | | 2023 |
| Discovery and validation of AMBLor as a prognostic biomarker for non-ulcerated cutaneous AJCC stage I/II melanoma. P Lovat, T Ewen, S Podlipnik, S Puig, J Malvehy, P Clark, C Lewis, ... Journal of Clinical Oncology 41 (16_suppl), 9573-9573, 2023 | | 2023 |
| Performance analysis of four machine learning algorithms for the accurate prediction of metastatic disease in cutaneous squamous cell carcinoma. TW Andrew, I Bolnykh, AL Bowes, SASG Fernando, A Nair, SNP Martin, ... Journal of Clinical Oncology 41 (16_suppl), e13579-e13579, 2023 | | 2023 |
| Programmed cell death-1 receptor-mediated regulation of Tbet+NK1.1− innate lymphoid cells within the tumor microenvironment JX Lim, CY Lai, GE Mallett, D McDonald, G Hulme, S Laba, A Shapanis, ... Proceedings of the National Academy of Sciences 120 (18), e2216587120, 2023 | 5 | 2023 |
| 1235 Endothelial AMBRA1 and Claudin5 as potential biomarkers of metastases in early-stage melanoma I Cosgarea, R Stout, K Best, P Sloan, J Armstrong, P Lovat Journal of Investigative Dermatology 143 (5), S212, 2023 | | 2023 |
| Clinical management of oropharyngeal squamous cell carcinoma P Lovat US Patent App. 17/633,073, 2022 | 4 | 2022 |
| 463 Implications of the ds-RNA stress response in melanoma cell lines and patient samples S Sadeq, P Lovat, G Nelson, D Mcdonald, A Filby, A Werner Journal of Investigative Dermatology 142 (12), S260, 2022 | | 2022 |
| Biomarkers for disease progression in squamous cell carcinoma M Labus, P Lovat, R Ellis, A Mcconnell US Patent App. 17/594,939, 2022 | | 2022 |
| AMBLor: an immunohistochemical prognostic biomarker to identify low-risk nonulcerated cutaneous AJCC stage I/II melanomas P Sloan, T Ewen, G Paragh, P Bogner, A Hussain, N Stefanos, P Barrett, ... BRITISH JOURNAL OF DERMATOLOGY 187, 143-144, 2022 | | 2022 |
| Loss of epidermal integrity and tumour ulceration in melanoma is driven by tumoral transforming growth factor-beta 2 secretion and mediated through AMBRA1 and claudin-1 … I Cosgarea, A McConnell, T Ewen, D Tang, A Greenwood, J Armstrong, ... BRITISH JOURNAL OF DERMATOLOGY 187 (1), E2-E2, 2022 | | 2022 |
